REMEGEN (09995): The company's current production and operations remain fully normal, and the commercialization of core products is progressing steadily.

REMEGEN (09995) issued an announcement that the company's current production and operations remain fully normal, its supply chain is stable, production capacity is adequately guaranteed, the commercialization of core products is progressing steadily, and overall operating quality continues to improve. Performance: In the first half of 2026, the company achieved operating revenue of RMB 5.853 billion, a year-on-year increase of 433.11%; net profit attributable to shareholders of the listed company was RMB 4.662 billion, compared with a loss of RMB 450 million in the same period last year, achieving a year-on-year turnaround from loss to profit; net cash flow from operating activities was RMB 4.214 billion, compared with RMB -246 million in the same period last year, with profit quality and operational resilience continuing to strengthen. Core product progress: (1) Telitacicept (RC18, trade name: Tai'ai): As of June 2026, telitacicept has been approved in China for five major indications: systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, Sjgren's syndrome, and immunoglobulin A nephropathy. Among them, the immunoglobulin A nephropathy indication was granted conditional approval by the National Medical Products Administration (NMPA) in June 2026, making it the world's first approved dual-target biologic for the treatment of IgA nephropathy; the Sjgren's syndrome indication was approved in the same period, making it the world's first dual-target innovative drug project for the treatment of Sjgren's syndrome to successfully complete Phase III clinical trials and achieve strongly positive results. In July 2026, telitacicept for injection was successfully included in the "National Essential Medicines List (2026 Edition)" under "immune system drugs." The new edition of the list included a total of 2 domestic Class I innovative biologics, and telitacicept is one of them, further improving drug accessibility and consolidating the market foundation in the autoimmune field. (2) Disitamab vedotin (RC48, trade name: Aidixi): In 2026, disitamab vedotin made important new progress in indication expansion. In March, its indication for adult breast cancer with HER2 low expression and liver metastasis was approved for marketing; in April, its indication in combination with toripalimab for first-line treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma was approved for marketing, making it the world's first HER2-ADC drug approved for this indication. Internationalization and BD cooperation: In January 2026, the company signed an exclusive licensing agreement with AbbVie for RC148, receiving a US$650 million upfront payment and becoming eligible to receive up to US$4.95 billion in milestone payments and double-digit sales royalties; to date, the company has completed global licensing for four core drugstelitacicept, disitamab vedotin, RC28, and RC148with cumulative total transaction value exceeding US$12.6 billion, as its internationalization strategy continues to be delivered. In the future, the company will continue to focus on core therapeutic areas such as autoimmune diseases and oncology, adhere to being driven by original innovation, steadily advance clinical research and commercialization of core products, and continuously enrich its product pipeline layout; at the same time, it will actively promote its internationalization strategy, deepen outbound licensing and global cooperation, and enhance market competitiveness. The company will also continue to strengthen R&D and production capacity building, optimize operating quality and operational efficiency, strictly fulfill information disclosure obligations in accordance with laws and regulations, and strive to create long-term value for shareholders.